Safety of catheter ablation for atrial fibrillation in patients with liver cirrhosis
Journal of Cardiovascular Electrophysiology · 2025
DOI: 10.1111/jce.16472 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von Nelson Barrera und 7 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Liver Cirrhosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Atrial fibrillation is the most prevalent cardiac arrhythmia, and catheter ablation (CA) has emerged as a viable treatment option for selected patients. However, its safety profile in liver cirrhosis (LC) populations remains underexplored.
Methods
This was an observational analysis of the National Inpatient Sample Database 2016–2020; we analyzed adult encounters undergoing CA for atrial fibrillation who had a concomitant diagnosis of LC. Using propensity scores, encounters were divided into two cohorts based on the presence or absence of LC and matched in a 1:1 fashion using LC as the dependent variable. In‐hospital mortality and postprocedure total complications were compared using regression models.
Results
93 830 procedures were identified for non‐LC patients and 960 involving LC patients; after propensity score matching, each cohort included 910 hospitalizations. The mean age in the LC‐matched cohort was 66.5 ± 9.1 years. In‐hospital mortality did not differ between the groups (aOR = 1.01; 95% CI [0.06–16.1]; p = .99). However, the LC cohort exhibited higher odds of total complications (aOR = 1.98; 95% CI [1.42–2.75]; p < .001). Length of stay (LOS) was comparable, but total costs were higher in the LC cohort: LOS was 2 days (95% CI [1–3]) in the LC group versus 3 days (95% CI [1–4]) ( p < .11) and LC: $202,000 (95% CI [$142 000–$261 000]) versus non‐LC: $189 000, (95% CI [$153 000–$222 000]) ( p < .0001).
Conclusion
In this national analysis of patients undergoing CA for AF, those with LC had similar in‐hospital mortality, postprocedure complications, and LOS compared to noncirrhotic patients. Furthermore, longitudinal studies are needed to assess the safety profile of CA in this subpopulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
- SBH Health System, Department of Internal Medicine, City University of New York School of Medicine, Bronx, New York, USA.
- Section of Cardiovascular Medicine, Yale New Haven Hospital, Yale University, New Haven, Connecticut, USA.
ORCID-Profile: Nelson Barrera, Roberto C Cerrud-Rodriguez, Luigi Di Biase
Zitieren
APA
Barrera, N., Jou, K., Malik, M., Gallegos-Koyner, F., Chamay, S., Elfert, K., Cerrud-Rodriguez, R. C., & Di Biase, L. (2025). Safety of catheter ablation for atrial fibrillation in patients with liver cirrhosis. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16472
Vancouver
Barrera N, Jou K, Malik M, Gallegos-Koyner F, Chamay S, Elfert K, et al. Safety of catheter ablation for atrial fibrillation in patients with liver cirrhosis. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.16472
BibTeX
@article{Barrera2025,
author = {Barrera, Nelson and Jou, Katerina and Malik, Mushrin and Gallegos-Koyner, Francisco and Chamay, Salomon and Elfert, Khaled and Cerrud-Rodriguez, Roberto C and Di Biase, Luigi},
title = {Safety of catheter ablation for atrial fibrillation in patients with liver cirrhosis},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2025},
doi = {10.1111/jce.16472}
}
EUVIMED